Join us anytime for an exciting exposition of digital therapeutics.
Providers caring for children and adolescents have seen a marked rise in mental health issues during the pandemic. Those practicing long enough recognize this escalation was present before the pandemic and has since worsened. They realize that this exacerbation has resulted in a higher demand for already limited behavioral health services. Although early intervention in mental health conditions is critical for achieving better outcomes, access to children’s immediate, safe, effective and private treatment programs has always been limited. There are many contributing factors to this problem, one being a short supply of trained and experienced therapists for this population. Additional challenges include providing treatment to a population confronted by healthcare disengagement, unaffordable treatment, mental health stigma, and inflexibility of existing treatments that lack patient autonomy.
While the surge in telepsychiatry and virtual counseling during the pandemic ameliorated some of these access issues, the demand for additional solutions emerged, resulting in a class of interventions called digital therapeutics (DTx). Unlike wellness or health apps, which are unregulated and are unable to make specific claims of disease treatment, mitigation or prevention, DTx undergo regulatory review to be cleared or certified to make such claims. Unfortunately, many providers are not familiar with these new therapies and may not know how to sort them out from the abundance of other unregulated digital devices.
In this webinar, we explore the growing market of DTx and how they are created, what regulatory scrutiny they are subjected to and how they are differentiated from other “off the shelf” products. We also dive into DTx designed to treat mental health conditions and how providers can incorporate these devices into their everyday treatment programs for their patients in a way that has never been possible before.